Wir überwinden Grenzen

Almost 64,000 men in Germany are diagnosed with prostate cancer every year, the most common cancer in men in this country. New approaches in the diagnosis and treatment of prostate cancer will be presented at the 7th Langendorff Symposium on July 14 and 15, 2017. The symposium is being organized by the Department of Radiation Oncology and the Department of Urology at the Medical Center - University of Freiburg. The two specialist departments at the Medical Center - University of Freiburg occupy a leading position in the treatment of prostate cancer. The conference will focus on further developments in the fields of imaging, epigenetics, immunology, surgery, robotics, hormone treatment and radiotherapy.

Scientists from the Medical Center - University of Freiburg have been able to contribute significant new findings in these research areas and would like to discuss them with nationally and internationally renowned scientists, including those from the Memorial Sloan Kettering Cancer Center (New York City, USA), the University Hospital Zurich (Switzerland) and Massachusetts General Hospital (Harvard University; Boston, USA). The experts will also discuss new possibilities for individualized therapy and the question of when it makes sense not to treat the tumor initially.

"Thanks to the enormous progress made in recent years, we are already able to cure many more patients than just a few years ago. This positive trend is continuing," said Prof. Dr. Anca-Ligia Grosu, Medical Director of the Department of Radiation Oncology at the Medical Center - University of Freiburg. She is chairing the 7th Langendorff Symposium together with Prof. Dr. Ulrich Wetterauer, Medical Director of the Department - University of Freiburg's Department of Urology.

One major goal that the experts will be addressing at the congress is individualized therapy. The aim is to assess the chances of success of a therapy very precisely before it begins, for example on the basis of imaging or molecular data. "This would allow us to avoid the burden of ineffective therapies and gain valuable time in the fight against cancer," says Professor Grosu.

At the 7th Langendorff Symposium, the experts will also discuss the question of when therapy is actually necessary based on the latest results. "It can make sense to just observe the tumor and wait and see with an intervention. However, such a procedure must be closely supervised by an experienced physician," says Prof. Wetterauer.

Further information on the 7th Langendorff Symposium can be found at:www.uniklinik-freiburg.de/index.php?id=15381

Contact:
Prof. Dr. Anca-Ligia Grosu
Medical Director
Department of Radiation Oncology
Medical Center - University of Freiburg
Phone: 0761 270-94610
anca.grosu@uniklinik-freiburg.de

Prof. Dr. Ulrich Wetterauer
Medical Director
Department of Urology
Medical Center - University of Freiburg
Phone: 0761 270-28910
ulrich.wetterauer@uniklinik-freiburg.de